Compare Heron Therapeutics Inc (HRTX) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Nokia Corp — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Nokia Corp trades at $10.7 (market cap $56.70B). The key difference: Nokia Corp is far larger — about 619.9× Heron Therapeutics Inc's market cap, and Nokia Corp pays a 1.63% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | NOK | |
|---|---|---|
Market Cap | $91.46M | $56.70B |
Sector | Health | Technology |
52-Week High | $1.96 | $16.83 |
52-Week Low | $0.39 | $4.05 |
Enterprise Value | $189.36M | $53.51B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Nokia (NOK) trades at $10.115, down 0.05% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed Q1 2026 earnings, missing EPS estimates, but has beaten expectations in prior quarters. Revenue for 2025 was $19.89B with a net income margin of 3.98%, while the P/E ratio stands at 63.48, indicating a premium valuation. Recent news highlights Nokia's strategic pivot to AI-powered networking, including partnerships with Nvidia and telecom providers.
The outlook for NOK is cautiously optimistic, driven by AI and 5G demand, but high valuation and recent earnings miss pose risks. Analyst consensus is a Buy with a $18.00 price target, suggesting significant upside. Key risks include execution on AI initiatives, competitive pressures, and supply chain constraints. The stock's performance hinges on delivering sustained growth from its AI infrastructure investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
